在进行治疗性抗凝治疗时联合使用凝血因子IIa和Xa抑制剂治疗血栓形成。 - Suppr

Combined factor IIa and Xa inhibitor therapy for thrombosis whilst on therapeutic anticoagulant.

作者信息

Arachchillage Deepa R J, Besser Martin, Maclean Rhona, Baglin Trevor, van Veen Joost J

机构信息

Department of Haematology, Imperial College Healthcare NHS Trust and Imperial College London, Hammersmith Hospital, 4th Floor, Commonwealth Building, Du Cane Road, London, W12 0NN, UK.

Addenbrooke's Hospital, Cambridge University Hospitals NHS Trust, Hills Road, Cambridge CB2 0QQ, UK.

出版信息

Thromb Res. 2016 Jul;143:137-40. doi: 10.1016/j.thromres.2016.05.007. Epub 2016 May 11.

DOI:10.1016/j.thromres.2016.05.007

PMID:27244105

Abstract

摘要

相似文献

Combined factor IIa and Xa inhibitor therapy for thrombosis whilst on therapeutic anticoagulant.

Thromb Res. 2016 Jul;143:137-40. doi: 10.1016/j.thromres.2016.05.007. Epub 2016 May 11.

[Not Available].

Lakartidningen. 2018 Dec 4;115:FAS3.

Direct oral anticoagulants in rare venous thrombosis.

Intern Emerg Med. 2016 Mar;11(2):167-70. doi: 10.1007/s11739-016-1398-6. Epub 2016 Feb 13.

[New - direct oral anticoagulants: actual review].

Vnitr Lek. 2016 Fall;62(10):805-813.

The new oral anticoagulants: Reasonable alternatives to warfarin.

Cleve Clin J Med. 2015 Dec;82(12):847-54. doi: 10.3949/ccjm.82a.14052.

Study protocol for the dabigatran, apixaban, rivaroxaban, edoxaban, warfarin comparative effectiveness research study.

J Comp Eff Res. 2018 Jan;7(1):57-66. doi: 10.2217/cer-2017-0053. Epub 2017 Dec 21.

Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation.

Thromb Res. 2016 Feb;138:22-29. doi: 10.1016/j.thromres.2015.12.023. Epub 2015 Dec 24.

Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation.

Chest. 2016 Dec;150(6):1302-1312. doi: 10.1016/j.chest.2016.07.013. Epub 2016 Sep 28.

Apixaban and rivaroxaban in patients with cerebral venous thrombosis.

Thromb Res. 2019 Jan;173:77-78. doi: 10.1016/j.thromres.2018.11.018. Epub 2018 Nov 20.

Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.

J Oncol Pharm Pract. 2018 Oct;24(7):494-500. doi: 10.1177/1078155217718382. Epub 2017 Jul 16.

引用本文的文献

New horizons in the pharmacological management of venous thromboembolism.

Hemasphere. 2025 Jun 3;9(6):e70143. doi: 10.1002/hem3.70143. eCollection 2025 Jun.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Combined factor IIa and Xa inhibitor therapy for thrombosis whilst on therapeutic anticoagulant.

作者信息

Arachchillage Deepa R J, Besser Martin, Maclean Rhona, Baglin Trevor, van Veen Joost J

机构信息

Department of Haematology, Imperial College Healthcare NHS Trust and Imperial College London, Hammersmith Hospital, 4th Floor, Commonwealth Building, Du Cane Road, London, W12 0NN, UK.

Addenbrooke's Hospital, Cambridge University Hospitals NHS Trust, Hills Road, Cambridge CB2 0QQ, UK.

出版信息

Thromb Res. 2016 Jul;143:137-40. doi: 10.1016/j.thromres.2016.05.007. Epub 2016 May 11.

DOI:10.1016/j.thromres.2016.05.007

PMID:27244105

Abstract

摘要

相似文献

Combined factor IIa and Xa inhibitor therapy for thrombosis whilst on therapeutic anticoagulant.

Thromb Res. 2016 Jul;143:137-40. doi: 10.1016/j.thromres.2016.05.007. Epub 2016 May 11.

[Not Available].

Lakartidningen. 2018 Dec 4;115:FAS3.

Direct oral anticoagulants in rare venous thrombosis.

Intern Emerg Med. 2016 Mar;11(2):167-70. doi: 10.1007/s11739-016-1398-6. Epub 2016 Feb 13.

[New - direct oral anticoagulants: actual review].

Vnitr Lek. 2016 Fall;62(10):805-813.

The new oral anticoagulants: Reasonable alternatives to warfarin.

Cleve Clin J Med. 2015 Dec;82(12):847-54. doi: 10.3949/ccjm.82a.14052.

Study protocol for the dabigatran, apixaban, rivaroxaban, edoxaban, warfarin comparative effectiveness research study.

J Comp Eff Res. 2018 Jan;7(1):57-66. doi: 10.2217/cer-2017-0053. Epub 2017 Dec 21.

Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation.

Thromb Res. 2016 Feb;138:22-29. doi: 10.1016/j.thromres.2015.12.023. Epub 2015 Dec 24.

Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation.

Chest. 2016 Dec;150(6):1302-1312. doi: 10.1016/j.chest.2016.07.013. Epub 2016 Sep 28.

Apixaban and rivaroxaban in patients with cerebral venous thrombosis.

Thromb Res. 2019 Jan;173:77-78. doi: 10.1016/j.thromres.2018.11.018. Epub 2018 Nov 20.

Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.

J Oncol Pharm Pract. 2018 Oct;24(7):494-500. doi: 10.1177/1078155217718382. Epub 2017 Jul 16.

引用本文的文献

New horizons in the pharmacological management of venous thromboembolism.

Hemasphere. 2025 Jun 3;9(6):e70143. doi: 10.1002/hem3.70143. eCollection 2025 Jun.

Combined factor IIa and Xa inhibitor therapy for thrombosis whilst on therapeutic anticoagulant.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Combined factor IIa and Xa inhibitor therapy for thrombosis whilst on therapeutic anticoagulant.

作者信息

机构信息

出版信息

相似文献

引用本文的文献